ATE254928T1 - Stabilisierte zusammensetzung mit nootropen wirkstoffen - Google Patents
Stabilisierte zusammensetzung mit nootropen wirkstoffenInfo
- Publication number
- ATE254928T1 ATE254928T1 AT99910793T AT99910793T ATE254928T1 AT E254928 T1 ATE254928 T1 AT E254928T1 AT 99910793 T AT99910793 T AT 99910793T AT 99910793 T AT99910793 T AT 99910793T AT E254928 T1 ATE254928 T1 AT E254928T1
- Authority
- AT
- Austria
- Prior art keywords
- acid
- active ingredients
- stabilized composition
- nootropic
- nootropic active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP1999/001686 WO2000059544A1 (fr) | 1999-03-31 | 1999-03-31 | Compositions stabilisees contenant des medicaments nootropes |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE254928T1 true ATE254928T1 (de) | 2003-12-15 |
Family
ID=14235351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99910793T ATE254928T1 (de) | 1999-03-31 | 1999-03-31 | Stabilisierte zusammensetzung mit nootropen wirkstoffen |
Country Status (8)
Country | Link |
---|---|
US (1) | US6372760B1 (de) |
EP (1) | EP1086706B1 (de) |
AT (1) | ATE254928T1 (de) |
DE (1) | DE69913138T2 (de) |
DK (1) | DK1086706T3 (de) |
ES (1) | ES2211056T3 (de) |
PT (1) | PT1086706E (de) |
WO (1) | WO2000059544A1 (de) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6193993B1 (en) * | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
US20050063998A1 (en) * | 1999-10-26 | 2005-03-24 | Francois Marc Karel Jozef | Oral solution containing galantamine and a sweetening agent |
US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
ATE345803T1 (de) | 2000-03-03 | 2006-12-15 | Eisai Co Ltd | Neue methoden unter verwendung von cholinesteraseinhibitoren |
EP1284729A4 (de) * | 2000-04-13 | 2007-12-19 | Mayo Foundation | A-(beta)-42 senkende arzneimittel |
JP4394443B2 (ja) * | 2001-10-17 | 2010-01-06 | 久光製薬株式会社 | 経皮吸収型製剤 |
CN100340293C (zh) * | 2002-02-07 | 2007-10-03 | 卫材R&D管理有限公司 | 毛发生长促进剂、适于经皮给药的制剂 |
IL150509A (en) | 2002-07-01 | 2007-07-04 | Joseph Kaspi | Pharmaceutical preparations containing donafazil hydrochloride |
US20060014801A1 (en) * | 2002-11-22 | 2006-01-19 | The Johns Hopkins University | Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs |
WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
US20070129549A1 (en) * | 2003-03-21 | 2007-06-07 | Yatendra Kumar | Stable lamotrigine pharmaceutical compositions and processes for their preparation |
KR20060040676A (ko) * | 2003-07-11 | 2006-05-10 | 미리어드 제네틱스, 인크. | 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형 |
CA2552221A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
US20070293538A1 (en) * | 2004-04-13 | 2007-12-20 | Myriad Genetics, Incorporated | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders |
US20050252144A1 (en) * | 2004-04-29 | 2005-11-17 | Macdonald Robert A | Veneers for walls, retaining walls and the like |
US20050267076A1 (en) * | 2004-05-14 | 2005-12-01 | Johns Hopkins University | Method for improving cognitive function |
WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
BRPI0514303A (pt) * | 2004-08-11 | 2008-06-10 | Myriad Genetics Inc | composição farmacêutica e método para tratar distúrbios neurodegenerativos |
HUP0401850A3 (en) * | 2004-09-15 | 2008-03-28 | Egis Gyogyszergyar Nyilvanosan | Donepezil salts for producing pharmaceutical composition |
DE102004046497A1 (de) * | 2004-09-23 | 2006-04-06 | Helm Ag | Donepezil-Salze |
US7592459B2 (en) * | 2004-09-29 | 2009-09-22 | Chemagis Ltd. | Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride |
PT1811957E (pt) * | 2004-10-19 | 2009-01-27 | Krka Tovarna Zdravil D D Novo | Composição farmacêutica sólida contendo cloridrato de donepezil |
EP1819681B1 (de) * | 2004-11-23 | 2009-08-12 | Warner-Lambert Company LLC | 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure-derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia |
AU2005320547B2 (en) * | 2004-12-27 | 2009-02-05 | Eisai R & D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
JP5084496B2 (ja) * | 2005-02-04 | 2012-11-28 | 久光製薬株式会社 | 経皮吸収貼付剤 |
WO2007010910A1 (en) * | 2005-07-15 | 2007-01-25 | Eisai R & D Management Co., Ltd. | 1-benzyl-4-[(5, 6-dimethoxy-1-indanon)-2-yl]-methyl piperidine p-toluenesulfonate or crystal thereof |
AU2006272760A1 (en) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
WO2008006099A2 (en) * | 2006-07-07 | 2008-01-10 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
GB0614586D0 (en) * | 2006-07-22 | 2006-08-30 | Pliva Istrazivacki Inst D O O | Pharmaceutical Formulation |
MX2009004516A (es) | 2006-10-27 | 2009-08-12 | Medivation Neurology Inc | Metodos y terapias de combinacion para tratar enfermedad de alzheimer. |
CA2671006A1 (en) * | 2006-12-01 | 2008-06-05 | Nitto Denko Corporation | Method for suppressing discoloration over time of adhesive preparation containing donepezil |
CN101568340B (zh) * | 2006-12-01 | 2011-06-15 | 日东电工株式会社 | 经皮吸收制剂 |
JP5037522B2 (ja) * | 2006-12-01 | 2012-09-26 | 日東電工株式会社 | 安定化されたドネペジル含有貼付製剤 |
JP5110711B2 (ja) * | 2006-12-01 | 2012-12-26 | 日東電工株式会社 | 安定化されたドネペジル含有貼付製剤 |
DE102007034633A1 (de) * | 2007-04-05 | 2009-01-29 | Nano-X Gmbh | Beschichtungsmaterial mit einer katalytischen Aktivität und Verwendung des Beschichtungsmaterials |
DE102007016946A1 (de) | 2007-04-05 | 2008-10-09 | Nano-X Gmbh | Beschichtungsmaterial mit einer katalytischen Aktivität und Verwendung des Beschichtungsmaterials |
US20110212928A1 (en) | 2010-02-09 | 2011-09-01 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
HUE028847T2 (en) | 2010-02-17 | 2017-01-30 | Veloxis Pharmaceuticals As | Stabilized tacrolimus preparation |
EP2366378A1 (de) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Donepezilformulierungen mit verzögerter Freisetzung |
WO2011127235A1 (en) | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
GR1007368B (el) | 2010-05-27 | 2011-08-02 | Alapis Α.Β.Ε.Ε., | Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας |
WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
WO2012053016A1 (en) | 2010-10-22 | 2012-04-26 | Cadila Healthcare Limited | Sustained release pharmaceutical compositions of donepezil |
US8349376B1 (en) | 2011-03-08 | 2013-01-08 | Bezzek Mark S | Anti-dementia regimen |
US8846061B1 (en) | 2011-03-08 | 2014-09-30 | Mark S. Bezzek | Multivitamin-mineral regimens for longevity and wellness |
EP2502620A1 (de) | 2011-03-24 | 2012-09-26 | Krka Tovarna Zdravil, D.D., Novo Mesto | Feste pharmazeutische Zusammensetzung mit Donepezil |
WO2014007774A1 (en) | 2012-07-02 | 2014-01-09 | Mahmut Bilgic | Water soluble formulations comprising a piperidine derivative active agent |
US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
US11160785B2 (en) | 2013-03-15 | 2021-11-02 | Agenebio Inc. | Methods and compositions for improving cognitive function |
JP6899043B2 (ja) | 2015-05-22 | 2021-07-07 | エージンバイオ, インコーポレイテッド | レベチラセタムの持続放出性医薬組成物 |
KR101982018B1 (ko) | 2015-12-21 | 2019-05-24 | 주식회사 에프티넷 | 리튬 조촉매를 첨가하여 촉매의 활성도를 증가시킨 촉매 코팅 필터 |
US10369187B2 (en) | 2017-02-09 | 2019-08-06 | Vanderbilt University | Peptide regulators of JNK family kinases |
WO2020111719A2 (ko) * | 2018-11-26 | 2020-06-04 | 연세대학교 산학협력단 | 도네페질 공융혼합물 및 이의 용도 |
KR102115102B1 (ko) | 2018-12-21 | 2020-05-26 | 동아에스티 주식회사 | 안정화된 도네페질 함유 경피 흡수제제 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3247676A1 (de) * | 1982-12-23 | 1984-06-28 | A. Nattermann & Cie GmbH, 5000 Köln | Galenische form fuer amitriptylinoxid und verfahren zur herstellung |
US5428043A (en) * | 1990-02-08 | 1995-06-27 | Pfizer Inc. | Tricyclic-cyclic amines as novel cholinesterase inhibitors |
US5153193A (en) * | 1991-10-01 | 1992-10-06 | Hoechst-Roussel Pharmaceuticals Incorporated | Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs |
US5177070A (en) * | 1991-11-15 | 1993-01-05 | Ciba-Geigy Corporation | Method of treating physiologic male erectile impotence |
JP2770571B2 (ja) | 1993-04-28 | 1998-07-02 | 吉富製薬株式会社 | 安定化された注射剤および注射剤の安定化法 |
US6323195B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
JP3136306B2 (ja) | 1993-10-26 | 2001-02-19 | 丸石製薬株式会社 | 静脈注射用ニトロプルシドナトリウム注射剤 |
GB9514821D0 (en) * | 1995-07-19 | 1995-09-20 | Sod Conseils Rech Applic | Galanthamine derivatives |
US5962535A (en) * | 1997-01-17 | 1999-10-05 | Takeda Chemical Industries, Ltd. | Composition for alzheimer's disease |
JP3797764B2 (ja) * | 1997-10-01 | 2006-07-19 | エーザイ株式会社 | 光安定化組成物 |
KR100746753B1 (ko) * | 1998-08-28 | 2007-08-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고미 등을 경감한 의약조성물 |
-
1999
- 1999-03-31 AT AT99910793T patent/ATE254928T1/de active
- 1999-03-31 DK DK99910793T patent/DK1086706T3/da active
- 1999-03-31 DE DE69913138T patent/DE69913138T2/de not_active Expired - Lifetime
- 1999-03-31 ES ES99910793T patent/ES2211056T3/es not_active Expired - Lifetime
- 1999-03-31 PT PT99910793T patent/PT1086706E/pt unknown
- 1999-03-31 EP EP99910793A patent/EP1086706B1/de not_active Expired - Lifetime
- 1999-03-31 US US09/700,342 patent/US6372760B1/en not_active Expired - Lifetime
- 1999-03-31 WO PCT/JP1999/001686 patent/WO2000059544A1/ja active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
DK1086706T3 (da) | 2004-03-08 |
DE69913138D1 (de) | 2004-01-08 |
PT1086706E (pt) | 2004-02-27 |
EP1086706A1 (de) | 2001-03-28 |
US6372760B1 (en) | 2002-04-16 |
ES2211056T3 (es) | 2004-07-01 |
EP1086706A4 (de) | 2002-05-22 |
WO2000059544A1 (fr) | 2000-10-12 |
EP1086706B1 (de) | 2003-11-26 |
DE69913138T2 (de) | 2004-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE254928T1 (de) | Stabilisierte zusammensetzung mit nootropen wirkstoffen | |
EE200000759A (et) | Farmatseutilised kompositsioonid kahe või enama toimeainega aerosoolidele | |
DE60105448D1 (de) | Feste dispersionen mit nitrataktiven wirkstoffen | |
HUP9802725A3 (en) | Phthalic acid diamide derivatives, agricultural and horticultural insecticide compositions containing these compounds as active ingredients and use thereof | |
NO20026037L (no) | Sötvareprodukt som inneholder aktive bestanddeler | |
DE60230340D1 (de) | N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung | |
NO20040564L (no) | Karboksylsyrederivatforbindelser og legemidler omfattende disse forbindelser som den aktive bestanddel | |
MX9304710A (es) | Composicion farmaceutica y/o cosmetica y su uso. | |
ATE269069T1 (de) | Orale zubereitung enthaltend einen biguanid und eine organische säure | |
NO942299L (no) | Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin | |
FR2689396B1 (fr) | Piégeur d'oxygène actif. | |
ATE260650T1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
DE60317039D1 (de) | Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben | |
DE60136909D1 (de) | Arzneimittel mit anemonin als aktivum zur behandlung von aseptischer inflammation | |
PL366855A1 (en) | Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof | |
DE60001266D1 (de) | Betahistin-hältige formulierung mit kontrollierter wirkstofffreisetzung | |
ATE411802T1 (de) | Kombinationspräparate von 1,4- benzothiepin-1,1- dioxidderivaten mit weiteren wirkstoffen und deren verwendung | |
ATE395064T1 (de) | Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen | |
DK0617035T3 (da) | Hetero-tricyclisk-substituerede phenyl-cyclohexan-carboxylsyrederivater. | |
DE60302951D1 (de) | Pyroglutaminsäure-salz von Amlodipin | |
MXPA04005033A (es) | Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes. | |
CY1106882T1 (el) | Τροποποιηση βητακυτταρουλινης | |
ATE526833T1 (de) | Teigzusammensetzung enthaltend eingekapselte organische säure und antimikrobiellen wirkstoff | |
DE60003188D1 (de) | Paracetamol und drotaverin enthaltende zusammensetzung | |
NO20041878D0 (no) | Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1086706 Country of ref document: EP |